Eleva confirms dry AMD as second indication for proprietary Factor H (CPV-104) program

Eleva确认干性AMD为专有因子H（CPV-104）计划的第二个适应症

FREIBURG IM BREISGAU, Germany, April 15, 2025 / Biotech Newswire / --

德国弗赖堡，2025年4月15日 /生物技术新闻社/ --

Eleva

提升

, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, announced today the publication of new data on its lead pipeline asset Factor H (CPV-104) in the peer-reviewed

，一家基于突破性技术平台发现和开发以前无法获取的生物制剂的先驱公司，今天宣布了其主要管线资产Factor H（CPV-104）的新数据在同行评审的期刊上发表。

Journal of Neuroinflammation

神经炎症杂志

. In an established animal model of age-related macular degeneration (AMD), Eleva’s recombinant human Factor H improved two hallmarks of the disease by statistically significantly dampening the inflammatory activity of microglia and Müller cells in the eye and attenuating light-induced retinal degeneration.

在已建立的与年龄相关的黄斑变性（AMD）动物模型中，Eleva的重组人因子H通过显著降低眼部小胶质细胞和穆勒细胞的炎症活性，并减轻光诱导的视网膜退化，改善了该疾病的两个重要特征。

To review the full publication, please .

要查看完整的出版物，请。

click here

点击这里

.

。

“Our innovative Factor H (CPV-104) program continues to generate positive data underlining its broad potential in both complement-related rare disorders and larger indications that correlate with complement deregulation like dry AMD,”

“我们创新的Factor H（CPV-104）项目继续产生积极的数据，突显了其在补体相关罕见疾病和与补体失调相关的较大适应症（如干性AMD）中的广泛潜力。”

commented Andreas Schaaf, Ph.D., Chief Scientific Officer of Eleva.

Eleva的首席科学官Andreas Schaaf博士评论道。

“The

“The

in vivo

体内

data published today bode well for the ongoing expansion of the development program into additional indications branching out from our initial focus on C3 Glomerulopathy (C3G).”

今天发布的数据预示着开发计划将持续扩展到更多的适应症，从我们最初关注的C3肾小球病（C3G）延伸出去。

Dry AMD is a degenerative disease of the retina that can lead to blindness, primarily affecting elderly patients. The complement system plays a central role in dry AMD, driving chronic inflammation and immune cell-mediated killing of retinal cells. The new study, published in collaboration with the University of Cologne, evaluated the effects of intravitreal injections of Factor H (CPV-104) on disease processes such as retinal degradation following light exposure, and indicators of the inflammatory process, such as microglia morphology, localization and migration patterns that drive disease progression.

干性AMD是一种视网膜退行性疾病，可导致失明，主要影响老年患者。补体系统在干性AMD中起核心作用，驱动慢性炎症和免疫细胞介导的视网膜细胞杀伤。这项新研究与科隆大学合作发表，评估了玻璃体内注射因子H（CPV-104）对疾病进程的影响，例如光暴露后的视网膜退化，以及炎症过程的指标，如小胶质细胞形态、定位和迁移模式对疾病进展的驱动作用。

The results provide insights into the neuroprotective and immunomodulatory potential of a human Factor H’s (CPV-104) treatment, indicating that it may be used to delay or prevent dry AMD disease progression in humans..

结果提供了关于人类因子H（CPV-104）治疗的神经保护和免疫调节潜力的见解，表明它可能用于延缓或预防人类干性AMD疾病的进展。

The full publication, entitled “Moss-derived human complement factor H modulates retinal immune response and attenuates retinal degeneration” is available on the

完整的出版物，标题为“苔藓衍生的人类补体因子H调节视网膜免疫反应并减轻视网膜变性”，可在

Journal of Neuroinflammation

神经炎症杂志

website

网站

.

。

+++ Meet the Eleva team during the LSX World Congress in London, April 28-30, 2025, to learn more about future collaboration and investment opportunities +++

+++ 2025年4月28日至30日，在伦敦举行的LSX世界大会上与Eleva团队会面，了解更多关于未来合作与投资机会 +++

About

关于

Eleva

提升

Eleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biologics based on a breakthrough moss-based technology platform. The company’s proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025.

Eleva是一家临床阶段的生物制药公司，基于突破性的苔藓技术平台发现和开发以前无法获得的生物制品。该公司专有的研发管线包括用于补体疾病和酶替代疗法的候选药物。重组人补体因子H（CPV-104）预计将于2025年上半年进入C3肾小球病（C3G）的临床研究。

Dry AMD has been selected as the second indication. The company’s aGal (RPV-001) program to treat Fabry disease has completed a positive Phase 1b clinical trial. All programs are sourced from Eleva’s transformative moss-based technology platform, which allows lab to GMP-scale manufacturing of previously undruggable human proteins with tremendous therapeutic potential..

干性AMD已被选为第二个适应症。该公司治疗法布里病的aGal（RPV-001）项目已完成积极的1b期临床试验。所有项目均源自Eleva具有变革性的苔藓技术平台，该平台能够以前所未有的治疗潜力实现以往无法成药的人类蛋白从实验室到GMP规模的生产。

Contacts

联系人

Eleva

提升

Fabienne Zeitter

法比安·塞特

Director Marketing

营销总监

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

+49 761 470 99 0

+49 761 470 99 0

Valency Communications

价通信

Mario Brkulj

马里奥·布鲁克利

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

+49 160 9352 9951

+49 160 9352 9951

Investor Contact

投资者联系

Cohesion Bureau

凝聚力局

Giovanni Ca’ Zorzi

乔瓦尼·卡·佐尔齐

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

+33 7 84 67 07 27

+33 7 84 67 07 27

Keywords: Animals; Complement Factor H; Retinal Degeneration; Microglia; Neuroprotection; Macular Degeneration; Retina; Inflammation; Complement System Proteins; Immunomodulation; Biological Therapy; Models, Animal; Blindness; Eleva; Factor H; CPV-104; dry AMD; age-related macular degeneration; neuroprotection; preclinical study; recombinant human Factor H; Journal of Neuroinflammation; Müller cells; complement system; C3 Glomerulopathy; C3G; intravitreal injections; retinal immune response; complement deregulation; moss-derived biologics; biologics; moss-based technology platform; enzyme replacement therapies.

关键词：动物；补体因子H；视网膜退化；小胶质细胞；神经保护；黄斑变性；视网膜；炎症；补体系统蛋白；免疫调节；生物治疗；动物模型；失明；Eleva；因子H；CPV-104；干性AMD；年龄相关性黄斑变性；神经保护；临床前研究；重组人因子H；神经炎症杂志；穆勒细胞；补体系统；C3肾小球病；C3G；玻璃体内注射；视网膜免疫反应；补体失调；苔藓源生物制品；生物制品；苔藓技术平台；酶替代疗法。

Source: Biotech Newswire

来源：生物技术新闻专线